Intravenous Immunoglobulins: Are They Helpful?

Conference paper


While there is increasing knowledge on the mechanisms of biological efficacy of intravenous immunoglobulins(IVIG), their clinical effectiveness in septic patients remains a matter of controversy. At present, data suggest potential beneficial effects regarding a reduction in morbidity after IVIG prophylaxis or early treatment in selected patients. However, no large-sized controlled clinical trial has yet been able to document a significant reduction in mortality by IVIG treatment for the total population of adult septic patients.


Intravenous Immunoglobulin IVIG Treatment Critical Illness Polyneuropathy Immunoglobulin Preparation IVIG Administration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Pollack M (1983) Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis 147:1090–1098PubMedCrossRefGoogle Scholar
  2. 2.
    Fischer GW, Hunter KW, Hemming VG et al (1983) Functional antibacterial activity of a human intravenous immunoglobulin preparation: In vitro and in vivo studies. Vox Sang 44: 296–299PubMedCrossRefGoogle Scholar
  3. 3.
    Dalhoff A (1985) In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 13[Suppl 2]:S185–S191PubMedCrossRefGoogle Scholar
  4. 4.
    Andersson JP, Andersson UG (1990) Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 71:372–376PubMedGoogle Scholar
  5. 5.
    Horiuchi A, Abe Y, Miyake M et al (1993) Natural human IgG inhibits the production of tumor necrosis factor and interleukin-1 alpha through the Fc portion. Surgery Today 23: 241–245PubMedCrossRefGoogle Scholar
  6. 6.
    Skansen-Saphir U, Andersson J, Bjork L et al (1994) Lymphokine production induced by streptococcal pyrogenic exotoxin-A is selectively down-regulated by pooled human IgG. Eur J Immunol 24:916–922PubMedCrossRefGoogle Scholar
  7. 7.
    Shimozato T, Iwata M, Tamura N (1990) Suppression of tumor necrosis factor alpha production by a human immunoglobulin preparation for intravenous use. Infect Immun 58: 1384–1390PubMedGoogle Scholar
  8. 8.
    Amran D, Renz H, Lack G et al (1994) Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin Immunol Immunpathol 73:180–186CrossRefGoogle Scholar
  9. 9.
    Svenson M, Hansen MB, Bendtzen K (1993) Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 92:2533–2539PubMedCrossRefGoogle Scholar
  10. 10.
    Pilz G, Fateh-Moghadam S, Vieil B et al (1993) Supplemental immunoglobulin therapy in sepsis and septic shock — comparison of mortality under treatment with polyvalent i.v. immunoglobulin versus placebo. Protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 8:61–83Google Scholar
  11. 11.
    The Intravenous Immunoglobulin Collaborative Study Group (1992) Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med 327:234–240CrossRefGoogle Scholar
  12. 12.
    Werdan K, Pilz G, and the SBITS Study Group (1997) Polyvalent immune globulins. Shock 7 [Suppl 1]:5Google Scholar
  13. 13.
    Dominioni L, Dionigi R, Zanello M et al (1991) Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 126:236–240PubMedCrossRefGoogle Scholar
  14. 14.
    Schedel I, Dreikhausen U, Nentwig B et al (1991) Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Crit Care Med 19:1104–1113PubMedCrossRefGoogle Scholar
  15. 15.
    Werdan K, Pilz G (1992) Treatment of Gram-negative septic shock with an immunoglobulin. Letter to the Editor. Crit Care Med 20:1364–1365PubMedGoogle Scholar
  16. 16.
    Wortel CH, Dellinger P (1993) Treatment of Gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. Letter to the Editor. Crit Care Med 21:163–165PubMedCrossRefGoogle Scholar
  17. 17.
    Cafiero F, Gipponi M, Bonalumi U et al (1992) Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: Results of a randomized, multicenter clinical trial. Surgery 112:24–31PubMedGoogle Scholar
  18. 18.
    Pilz G, Kreuzer E, Kaab S et al (1994) Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified high-risk patients. Chest 105:76–82(Errata in 105:1924)PubMedCrossRefGoogle Scholar
  19. 19.
    Kuhn C, Muller-Werdan U, Pilz G et al (1997) Early risk stratification of patients after cardiac surgery using extracorporeal circulation — identification of an escalating systemic inflammatory response syndrome. Eur Heart J 18[Suppl]:585Google Scholar
  20. 20.
    Petros AJ, Marshall JC, van Saene HKF (1995) Should morbidity replace mortality as an end-point for clinical trials in intensive care? Lancet 345:369–371PubMedCrossRefGoogle Scholar
  21. 21.
    Knaus WA, Wagner DP, Zimmerman JE et al (1993) Variations in mortality and length of stay in intensive care units. Ann Intern Med 118:753–761PubMedGoogle Scholar
  22. 22.
    Knaus WA, Draper EA, Wagner DP et al (1985) APACHE II: A severity of disease classification system. Crit Care Med 13:818–829PubMedCrossRefGoogle Scholar
  23. 23.
    Pilz G, Appel R, Kreuzer E et al (1997) Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest 111:419–426PubMedCrossRefGoogle Scholar
  24. 24.
    Mohr M, Englisch L, Roth A et al (1997) Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 23:1144–1149PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1999

Authors and Affiliations

  • G. Pilz

There are no affiliations available

Personalised recommendations